Dr. Xiaozhen (Shawn) Yu

Cooley advised IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer innovative drugs based on synthetic lethality on its license and collaboration agreement with Eikon Therapeutics, a biotechnology company.

Cooley advised the underwriters in LumiraDx Limited’s $100.3 million aggregate financing, consisting of (1) a $75.3 million follow-on offering of 43,000,000 shares of common stock at a public offering price of $1.75 per share and (2) a $25.0 million concurrent private placement with the Bill & Melinda Gates Foundation. LumiraDx is a diagnostics company manufacturing and commercializing an innovative diagnostic platform that supports a broad menu of tests with lab-comparable performance at the point of care. Partners Denny Won, Kristin VanderPas, Charlie Kim and Dave Peinsipp led the Cooley team.

Cooley advised the underwriters on SOPHiA Genetics’ $234 million initial public offering of 13,000,000 ordinary shares. J.P. Morgan Securities LLC, Morgan Stanley & Co., Cowen and Company, LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. SOPHiA Genetics, whose securities now trade on the Nasdaq Global Select Market under the symbol “SOPH,” is the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine. Partners Richard Segal, Div Gupta and Eric Blanchard led the Cooley team.

Cooley advised the underwriters on Singular Genomics Systems’ $258.1 million initial public offering of 11,730,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. UBS Securities acted as a book-running manager for the offering, and J.P. Morgan Securities, Goldman Sachs, BofA Securities, and Cowen and Company acted as joint book-running managers. Singular Genomics Systems, whose securities now trade on the Nasdaq Global Select Market  under the symbol OMIC, is a life sciences technology company. Partners Charlie Kim, Sean Clayton and Kristin VanderPas led the Cooley team.

Cooley advised the underwriters on Olink Holding’s $406 million initial public offering of 20,294,116 American Depositary Shares, which includes the full exercise of the underwriters’ option to purchase additional shares. Goldman Sachs and Morgan Stanley acted as lead book-running managers for the offering and SVB Leerink acted as a joint book-running manager for the offering. Olink, whose securities now trade on the Nasdaq Global Market under the symbol OLK, is a company dedicated to accelerating proteomics together with the scientific community. Partners Richard Segal, Charlie Kim, Eric Blanchard and Madison Jones led the Cooley team.